Related Experiment Video
Updated: Oct 14, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
X-linked myotubular myopathy
Michael W Lawlor1, James J Dowling2
1Department of Pathology and Laboratory Medicine and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract:
X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disease caused by mutation in the MTM1 gene. MTM1 encodes myotubularin (MTM1), an endosomal phosphatase that acts to dephosphorylate key second messenger lipids PI3P and PI3,5P2. XLMTM is clinically characterized by profound muscle weakness and associated with multiple disabilities (including ventilator and wheelchair dependence) and early death in most affected individuals. The disease is classically defined by characteristic changes observed on muscle biopsy, including centrally located nuclei, myofiber hypotrophy, and organelle disorganization. In this review, we highlight the clinical and pathologic features of the disease, present concepts related to disease pathomechanisms, and present recent advances in therapy development.
Insights
X-linked myotubular myopathy (XLMTM) is a severe genetic muscle disorder. This review covers its pathology, mechanisms, and recent therapeutic advancements for this debilitating condition.
Area of Science:
- Biochemistry
- Genetics
- Pathology
Background:
- X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disease.
- It stems from mutations in the MTM1 gene, encoding the myotubularin (MTM1) phosphatase.
- XLMTM causes profound muscle weakness, disability, and early mortality.
Purpose of the Study:
- To review the clinical and pathological features of XLMTM.
- To discuss the underlying pathomechanisms of the disease.
- To highlight recent progress in therapeutic strategies for XLMTM.
Main Methods:
- Literature review of clinical studies and research.
- Analysis of pathological findings from muscle biopsies.
- Synthesis of current knowledge on disease mechanisms and therapies.
Main Results:
- XLMTM is characterized by specific muscle biopsy findings like central nuclei and myofiber hypotrophy.
- MTM1's role in dephosphorylating PI3P and PI3,5P2 is crucial.
- Advances in therapy development are emerging for this condition.
Conclusions:
- Understanding XLMTM's clinical, pathological, and mechanistic aspects is key.
- Therapeutic development offers hope for patients with this severe genetic disorder.
Related Concept Videos
Sex-linked Disorders
Satellite Stem Cells and Muscular Dystrophy
X-linked Traits
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cross-bridge Cycle
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

